Miss Kathryn Smart

2024

• Hopkins, G. et al. 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44(6), article number: 147. (10.1007/s10875-024-01739-0)
• Hulin-Curtis, S. et al. 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43(6), article number: 114259. (10.1016/j.celrep.2024.114259)

2022

• Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2(12), pp. 1641-1656. (10.1158/2767-9764.CRC-21-0123)
• Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127, pp. 1595–1602. (10.1038/s41416-022-01917-0)
• Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13, article number: 5422. (10.1038/s41467-022-32985-8)

2021

• Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124, pp. 1552-1555. (10.1038/s41416-021-01283-3)
• Lauder, S. N., Milutinovic, S., Pires, A., Smart, K., Godkin, A. and Gallimore, A. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology., Vol. 163. Elsevier, pp. 59-75., (10.1016/bs.mcb.2020.09.007)

2020

• Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8(12), pp. 1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
• Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69, pp. 2063 - 2073. (10.1007/s00262-020-02603-x)
• Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
• Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32(2), article number: 107885. (10.1016/j.celrep.2020.107885)

2019

• Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19, article number: 98. (10.1186/s12876-019-1002-4)

2017

• Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
• Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
• Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)

2015

• Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6(28), pp. 24649-24659. (10.18632/oncotarget.5584)
• Ondondo, B. et al. 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145(1), pp. 94-104. (10.1111/imm.12430)

2014

• Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134(9), pp. 2156-2167. (10.1002/ijc.28556)

2013

• Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
• Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
• Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)

2012

• Humphreys, I. R. et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42(12), pp. 3235-3242. (10.1002/eji.201242575)
• Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72(21), pp. 5473-5482. (10.1158/0008-5472.CAN-12-1912)

2011

• Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)

2010

• Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)

2007

• Taylor, K. M. et al. 2007. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Molecular Medicine 13(7-8), pp. 396-406.